Literature DB >> 7684526

The costs of prostatectomy for benign prostatic hyperplasia.

K A Weis1, R S Epstein, D M Huse, P A Deverka, G Oster.   

Abstract

Using claims data for a 5% random sample of Medicare beneficiaries, we estimated the costs of surgical treatment for benign prostatic hyperplasia (BPH), including those related to the initial prostatectomy, the treatment of postsurgical complications, and reoperation within one year. We identified 14,480 men who underwent prostatectomy for BPH during 1986-1987, including 13,730 transurethral and 750 open procedures. Mean total inpatient costs (including all hospital charges and professional service fees) for these procedures were estimated to be $6,501 and $10,223, respectively. Among patients who underwent transurethral and open prostatectomy, we identified 938 (6.8%) and 39 (5.2%) individuals who had at least one readmission for postsurgical complications or reoperation. Total expected costs of transurethral and open prostatectomy, inclusive of readmissions for complications and reoperations within one year, were estimated to be $6,823 and $10,477, respectively. Our study indicates the economic burden represented by surgical treatment of BPH.

Entities:  

Mesh:

Year:  1993        PMID: 7684526     DOI: 10.1002/pros.2990220407

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

Review 1.  Changes in medicare reimbursement: impact on therapy for benign prostatic hyperplasia.

Authors:  Robert F Donnell
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 3.092

2.  The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.

Authors:  David A Taub; John T Wei
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 3.  Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.

Authors:  L M Eri; K J Tveter
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 4.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense?

Authors:  Mark D Stovsky; Katherine Rhee; David Hartke
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

6.  The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia.

Authors:  Katherine J O'Malley; Rajiv Dhir; Joel B Nelson; James Bost; Yan Lin; Zhou Wang
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

7.  Cystostomy-free open suprapubic transvesical prostatectomy: Is it a safe method?

Authors:  Abbas Hassanpour; Mohammad Mehid Hosseini; Alireza Yousefi; Reza Inaloo
Journal:  Urol Ann       Date:  2016 Apr-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.